http://orcid.org/0000-0001-7595-9329
References
- Ferreri AJM, Govi S, Pileri S, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol/Hematol. 2012;83:293–302.10.1016/j.critrevonc.2012.02.005
- Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14(3):219–28.10.1038/modpathol.3880289
- Kim HK, Kim BH, Kim SA, Shin JK, Sang JH, Kwo AY, et al. Endobronchial ALK-positive anaplastic large cell lymphoma presenting massive hemoptysis. Tuberc Respir Dis. 2015;78:390–5.10.4046/trd.2015.78.4.390
- Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69:993–7.10.1016/S0003-4975(99)01535-0
- Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998 Mar 6;91:2076–84.
- Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri S, Delsol G, et al. ALK expression defines a distinct group of T/null lymphomas (‘ALK lymphomas’) with a wide morphological spectrum. Am J Pathol. 1998 Sep 3;153:875–86.10.1016/S0002-9440(10)65629-5
- Lamant L, Meggetto F, Al Saati T, Brugieres L, De Paillerets BB, Dastugue N, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin’s disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996 Jan 1;87:284–91.
- Onciu M, Behm FG, Raimondi SC¸ Moore S¸ Harwood EL¸ Puri CH, et al. ALK-positive anaplastic karge cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavourable prognosis. Am J clin pathol. 2003;120:617–25.10.1309/WH8PNU9PK4RRV852
- Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971 Nov;31(11):1860–1.
- Savage KJ, Harris N, Vose J, Ullrich F, Jaffe E, Connors J, et al. ALK– anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008 Jun 12;111:5496–504.10.1182/blood-2008-01-134270
- Brugières L, Quartier P, Le Deley MC. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children – a report from the French Society of Pediatric Oncology. Ann Oncol. 2000 Jan 1;11:53–8.10.1023/A:1008352726155
- Falini B, Pulford K, Puccioriri A, Carbone A, De Wolf-Peeters C, Cordell J, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999 Nov 10;94:3509–15.
- Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A prediction model for aggressive non-Hodgkin lymphoma. N Engl J MED. 1993;329:987–94.
- Brugières L, Deley MC, Pacquement H, Meguerian-Bedyon Z, Terrier-Lacombe MJ, Robert A, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998 Nov 10;92:3591–8.
- Krieger G, Kreysing E, Kneba M. Long-term results with MACOPB and radiation therapy for aggressive lymphomas. Onkologie 2001 Feb;24(Suppl. 1):49–58.